It is known for a long time that drug company payments to doctors influence how many apioid prescriptions they write. But a new study free Friday offers the first suggestion that they may also be connected to overdose tolls in their churches.
Aggressive marketing of prescription narcotics over the past 20 years has remained widely for the staggering death toll of the opioid epidemic. But existing research supports that contention.
The new studio, well-known in Jama's Network Open, shows that counties receiving such payments later experience higher death rates – even when researchers are controlling many other possible influences. The study did not prove a cause and effect relationship; The link between the two is an association.
The study also suggests, surprisingly, that consistent, trust-building visits – such as periodic launches sponsored by Drug Sales Reps – make more of a prescription for a company's drugs than high-dollar payments to physicians.
"What seems to me most is not the amount of money doctors have paid, it was the number of times they were paid," said Magdalena Cerdá, an associate professor of population health and director of the Center for Opioid Epidemiology and Politics at the NYU School of Medicine.
Michael Barnett, Assistant Professor of Health Policy and Management at the Harvard University Hospital Chan School of Public Health, who has studied the role of physicians in the opioid epidemic, called the findings "deeply about the ragging" [opioid] Crisis that we all realize. "
The annual number of prescriptions for painkillers such as oxycodone, hydrocodone and methadone has decreased in recent years as physicians, states, and public health authorities have responded to the opioid epidemic. After overdosing the drug killed nearly 18,000 people in 2017, according to the Centers for Disease Control and Prevention, even though illegal Phenomenil has become the main driver of the opioid crisis.
And prescription painkillers – rather Herzhin or Phentanil – are often the first opioid to which consumers are exposed.
Former research has linked drug company marketing to Apioid prescribing, but the researchers said their study was the first to extend the comparison to overdose deaths.
The new federal federal state-of-the-art study on federal deaths across all county from 1 August 2014 to 31 December 2016, with payments to doctors for meals, talk, consulting and travel for the period from 1 August 2013 to 31 December. , 2015.
The one-year lag was an attempt to ensure that the payments influenced prescribing, rather than high-prescribing physicians, attracting bigger payments on drug companies. In March, Harvard researchers and CNN released an analysis that showed physicians who prescribed more opioids for more drug companies.
Barnett said that regardless of how the payments work, they are influential. Known in the trade as "detailing," the efforts do affect prescribe decision making, he said.
"What it does is create awareness. It will be closer to the top of your mind. It's easier to reach for them," Barnett said.
The new study found 434,754 payments totaling $ 39.7 million to 67,507 physicians – about one in every 12 doctors. Research has found that one in every five family physicians has received this type of marketing.
"Counties receiving such marketing subsequently experienced elevated mortality," they wrote. "In addition, Opioid prescribing rates are very much associated with opioid marketing."
In most of the country, this type of marketing is legal and unlimited. Another author of the research, Scott Hadland, a pediatrician and researcher with the Boston Medical Centers, is inviting center for addiction, saying drug sales represent playing a legitimate role in educating physicians about medications.
But he said physicians have other ways to learn about drugs such as conferences and continuous education courses. Reducing overdose deaths, physicians, drug companies, and government may have to regulate marketing, he said.
In 2017, New Jersey institutes a regulation that can cover the amount of marketing funds prescribed by drug companies. And last year, Oxyontin manufacturer Purdue Pharma was neglected in marketing the opioids to physicians.
America's pharmaceutical industry and manufacturers, the major trade group for the drug industry, said in a statement that prescribing patients in the management of pain patients "should be brought up about the fundamentals of acute and chronic pain management, the range of available Treatment options and significant benefits and risks. "